FIELD: biochemistry.
SUBSTANCE: invention relates to use of Axl as biomarker for detecting occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, where upregulation of Axl expression is indicative of occurrence of (EMT). Invention also relates to a methods for detecting occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Axl expression, to identification of substances capable of inhibiting or reversing EMT, to a method for prediction of susceptibility of a subject to treatment with an Axl inhibitor.
EFFECT: invention enables to use determination of expression of Axl as useful marker for detecting occurrence of EMT, which can be used for diagnosis, prediction and therapy of cancer.
18 cl, 12 dwg
